Screening Brief Intervention Referral to Treatment (SBIRT) in New Mexico

November 15, 2017 updated by: Friends Research Institute, Inc.

SBIRT in New Mexico

The purpose of this study is to compare the effectiveness in reducing drug use and its associated problems of a brief intervention for drug use delivered by a behavioral health counselor as compared to a brief intervention delivered by a computerized intervention.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Drug use is a significant cause of morbidity and mortality in the United States. Efforts to develop and rigorously evaluate methods to provide Screening, Brief Intervention and Referral to Treatment (SBIRT) for drug users are needed. Computerized screening and brief interventions in particular have the potential to circumvent some of the potential problems of integrating SBIRT delivered by a counselor into busy primary care settings. These interventions may reduce drug use among individuals who are using drugs but are not yet drug dependent.

Study Type

Interventional

Enrollment (Actual)

360

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Maryland
      • Baltimore, Maryland, United States, 21201
        • Friends Research Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 18 years or older
  • Moderate risk category on the ASSIST scores

Exclusion Criteria:

  • planning to move out of New Mexico in the next year
  • receipt of formal drug abuse treatment or a brief intervention for drug use in the past month.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Computerized Brief Intervention
Computerized one-session brief intervention for drug use
Behavioral: Computerized brief intervention
This is a brief computerized intervention focused on drug use of patients receiving primary care treatment in an outpatient setting. The intervention is delivered in one session.
Active Comparator: Counselor delivered brief intervention
This is a brief intervention focused on drug use delivered by a behavioral health counselor and based on motivational interviewing
Behavioral: Counselor delivered brief intervention
This is a one session brief intervention delivered in a primary care setting that is based on motivational interviewing.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Alcohol, Smoking & Substance Involvement Screening Test (ASSIST) Score
Time Frame: 3 months post-baseline
The ASSIST's Global Continuum of Illicit Drug Risk was used. A higher score is considered more severe risk. The scores range from 0 to 308.
3 months post-baseline
Hair Testing
Time Frame: 3 month post-baseline
The number of participants testing positive on Radioimmunoassay (RIA) Hair Testing for opiates, cocaine, amphetamine and tetrahydrocannabinol (THC)
3 month post-baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Human Immunodeficiency Virus (HIV) Drug Use Risk Assessment Battery Subscale
Time Frame: 3 months post-baseline
HIV Drug Use Risk Assessment Battery Subscale Score ranges from 0 to 22. A higher score is considered to be associated with higher risk.
3 months post-baseline
Alcohol, Smoking & Substance Involvement Screening Test (ASSIST) Score
Time Frame: 6 month post-baseline
ASSIST's Global Continuum of Illicit Drug Risk Score which ranges from 0 to 308. A higher score is associated with higher risk.
6 month post-baseline
Alcohol, Smoking & Substance Involvement Screening Test (ASSIST) Score
Time Frame: 12 months post-baseline
ASSIST's Global Continuum of Illicit Drug Risk Score which ranges from 0 to 308. A higher score is associated with higher risk.
12 months post-baseline
Hair Testing
Time Frame: 6 month post-baseline
The predicted probabilities for testing positive on Radioimmunoassay (RIA) Hair Testing for opiates, cocaine, amphetamine and tetrahydrocannabinol (THC), calculated from generalized estimating equations.
6 month post-baseline
Hair Testing
Time Frame: 12 month post-baseline
Predicted Probabilities for testing positive on the Radioimmunoassay (RIA) Hair Testing for opiates, cocaine, amphetamine and THC, calculated from generalized estimating equations.
12 month post-baseline
Human Immunodeficiency Virus (HIV) Risk Assessment Battery Subscale
Time Frame: 6 month post-baseline
HIV Drug Use Risk Assessment Battery Subscale Score ranges from 0 to 22. A higher score is considered to be associated with higher risk.
6 month post-baseline
Human Immunodeficiency Virus (HIV) Risk Assessment Battery Subscale Score
Time Frame: 12 month post-baseline
HIV Drug Use Risk Assessment Battery Subscale Score ranges from 0 to 22. A higher score is considered to be associated with higher risk.
12 month post-baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Friends Research Institute, Inc.

Collaborators

National Institute on Drug Abuse (NIDA)

Investigators

  • Principal Investigator: Robert P Schwartz, M.D., Friends Research Institute, Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2010

Primary Completion (Actual)

December 1, 2012

Study Completion (Actual)

July 1, 2015

Study Registration Dates

First Submitted

May 21, 2010

First Submitted That Met QC Criteria

May 25, 2010

First Posted (Estimate)

May 27, 2010

Study Record Updates

Last Update Posted (Actual)

December 12, 2017

Last Update Submitted That Met QC Criteria

November 15, 2017

Last Verified

November 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 08-08-173
  • R01DA026003 (U.S. NIH Grant/Contract)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Drug Abuse

Clinical Trials on Computerized brief intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe